 BeiGene Ltd NASDAQ: BGNE announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa zanubrutinib against Johnson Johnsons NYSE: JNJ Imbruvica ibrutinib in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The data is based on 415 of 652 patients followed for a minimum of 12 months. 